Table 4d. Interferons: Selected Clinical Data
Last Updated: December 16, 2021
The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for interferons. The studies summarized below are the randomized controlled trials that have had the greatest impact on the Panel’s recommendations.
Methods | Results | Limitations and Interpretation |
---|---|---|
ACTT-3: Multinational, Double-Blind RCT of Interferon Beta-1a and Remdesivir in Hospitalized Adults With COVID-191 | ||
Key Inclusion Criteria
Key Exclusion Criteria
Interventions
Primary Endpoint
Key Secondary Endpoints
| Participant Characteristics
Primary Outcome
Secondary Outcomes
| Key Limitation
Interpretation
|
WHO Solidarity Trial: Multinational, Open-Label, Adaptive RCT of IV or SUBQ Interferon Beta-1a or Other Repurposed Drugs in Hospitalized Adults With COVID-192 | ||
Key Inclusion Criteria
Interventions
Primary Endpoint
Key Secondary Endpoint
| Participant Characteristics
Primary Outcomes
Secondary Outcome
| Key Limitations
Interpretation
|
DisCoVeRy Solidarity Trial Add-On: Open-Label, Adaptive RCT of SUBQ Interferon Beta-1a Plus Lopinavir/Ritonavir, Lopinavir/Ritonavir, or Hydroxychloroquine in Hospitalized Adults With COVID-19 in France3 | ||
Key Inclusion Criteria
Interventions
Primary Endpoint
Key Secondary Endpoints
| Participant Characteristics
Primary Outcome
Secondary Outcomes
| Key Limitations
Interpretation
|
Single-Blind RCT of Peginterferon Lambda-1a for Treatment of Outpatients With Uncomplicated COVID-19 in the United States4 | ||
Key Inclusion Criteria
Key Exclusion criteria
Interventions
Primary Endpoint
Key Secondary Endpoints
| Participant Characteristics
Primary Outcome
Secondary Outcomes
Other Outcomes
| Key Limitation
Interpretation
|
Double-Blind RCT of Peginterferon Lambda in Outpatients With Laboratory-Confirmed COVID-19 in Canada5 | ||
Key Inclusion Criteria
Key Exclusion Criterion
Interventions
Primary Endpoint
Key Secondary Endpoints
| Participant Characteristics
Primary Outcome
Secondary Outcomes
Other Outcomes
| Key Limitation
Interpretation
|
Key: AE = adverse event; ALT = alanine transaminase; AST = aspartate aminotransferase; DM = diabetes mellitus; ECMO = extracorporeal membrane oxygenation; HCQ = hydroxychloroquine; HTN = hypertension; IFN = interferon; IV = intravenous; LPV/RTV = lopinavir/ritonavir; MV = mechanical ventilation; NIV = noninvasive ventilation; OS = ordinal scale; the Panel = the COVID-19 Treatment Guidelines Panel; PCR = polymerase chain reaction; PEG-IFN = pegylated interferon; RCT = randomized controlled trial; RDV = remdesivir; RT-PCR = reverse transcription polymerase chain reaction; SOC = standard of care; SpO2 = oxygen saturation; SUBQ = subcutaneous; ULN = upper limit of normal; VL = viral load |
References
- Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, Phase 3 trial. Lancet Respir Med. 2021;9(12):1365-1376. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34672949.
- WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497-511. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33264556.
- Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021;27(12):1826-1837. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34048876.
- Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021;12(1):1967. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33785743.
- Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a Phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021;9(5):498-510. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33556319.